Truist Financial reiterated their hold rating on shares of UiPath (NYSE:PATH – Free Report) in a research report sent to investors on Thursday morning, Marketbeat reports. They currently have a $14.00 price target on the healthcare company’s stock, down from their previous price target of $32.00.
Other equities research analysts have also recently issued reports about the company. Mizuho lifted their price objective on UiPath from $22.00 to $25.00 and gave the company a neutral rating in a research note on Thursday, March 14th. JPMorgan Chase & Co. raised UiPath from a neutral rating to an overweight rating and lifted their price objective for the company from $22.00 to $28.00 in a research note on Thursday, March 14th. Wells Fargo & Company lifted their price objective on UiPath from $24.00 to $25.00 and gave the company an equal weight rating in a research note on Thursday, March 14th. KeyCorp started coverage on UiPath in a research note on Monday, April 8th. They issued an overweight rating and a $27.00 price objective for the company. Finally, Morgan Stanley boosted their target price on UiPath from $17.00 to $25.00 and gave the stock an equal weight rating in a research note on Thursday, March 14th. Fifteen equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Hold and an average target price of $20.24.
UiPath Stock Down 34.0 %
NYSE:PATH opened at $12.07 on Thursday. UiPath has a 52 week low of $11.71 and a 52 week high of $27.87. The company has a market capitalization of $6.87 billion, a P/E ratio of -71.00 and a beta of 1.01. The stock’s fifty day moving average is $20.13 and its two-hundred day moving average is $22.06.
UiPath (NYSE:PATH – Get Free Report) last posted its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.10. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. The company had revenue of $405.25 million for the quarter, compared to the consensus estimate of $383.32 million. Sell-side analysts anticipate that UiPath will post -0.04 earnings per share for the current fiscal year.
Insider Transactions at UiPath
In other news, CFO Ashim Gupta sold 40,000 shares of the company’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $21.66, for a total transaction of $866,400.00. Following the completion of the transaction, the chief financial officer now directly owns 660,762 shares of the company’s stock, valued at approximately $14,312,104.92. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders sold 96,000 shares of company stock valued at $2,023,440. 22.37% of the stock is currently owned by corporate insiders.
Institutional Trading of UiPath
Several institutional investors and hedge funds have recently made changes to their positions in the company. Intech Investment Management LLC lifted its holdings in shares of UiPath by 3.1% in the 4th quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company’s stock valued at $356,000 after purchasing an additional 426 shares during the last quarter. 180 Wealth Advisors LLC lifted its holdings in shares of UiPath by 0.3% in the 4th quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company’s stock valued at $4,497,000 after purchasing an additional 492 shares during the last quarter. Global Financial Private Client LLC lifted its holdings in shares of UiPath by 9.3% in the 1st quarter. Global Financial Private Client LLC now owns 6,471 shares of the healthcare company’s stock valued at $144,000 after purchasing an additional 551 shares during the last quarter. Bleakley Financial Group LLC raised its stake in UiPath by 4.9% during the 4th quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after acquiring an additional 598 shares during the last quarter. Finally, Simplicity Solutions LLC raised its stake in UiPath by 4.9% during the 4th quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after acquiring an additional 598 shares during the last quarter. 62.50% of the stock is owned by hedge funds and other institutional investors.
About UiPath
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.
Featured Articles
Receive News & Ratings for UiPath Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for UiPath and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
